Development of TDP-43 nuclear targeting aptamers for ALS/FTD
用于 ALS/FTD 的 TDP-43 核靶向适体的开发
基本信息
- 批准号:10558610
- 负责人:
- 金额:$ 8.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:Amyotrophic Lateral SclerosisAttenuatedAutopsyBenchmarkingBindingBiological AssayBroccoli - dietaryCell NucleusCellsChemistryChromatinComplexCytoplasmDNA BindingDataDevelopmentDiffuseDiseaseDissociationDoseDoxycyclineEnsureEnterobacteria phage MS2EvaluationEvolutionExonsFrontotemporal DementiaFutureGeneticGenetic TranscriptionHela CellsHistone H2BHistone H3Histone H4Immunofluorescence ImmunologicImmunoprecipitationInterventionLaboratoriesLengthLinkMALAT1 geneMS2 coat proteinMass Spectrum AnalysisMediatingMessenger RNAMicroRNAsMicroscopyMonitorMutationNeurodegenerative DisordersNeuronsNuclearNuclear ExportNuclear RNANucleotidesPathogenesisPathogenicityPathologicPatientsPlasmidsPoly ARNARNA BindingRNA SplicingRNA-Binding ProteinsRegulationResearchRibonucleoproteinsSmall Nucleolar RNAStructureSystemTDP-43 aggregationTestingTherapeuticTimeTransfectionU6 small nuclear RNAaptamerarmbeta Globinconfocal imagingcrosslinkcrosslinking and immunoprecipitation sequencingdesigneffective therapyfrontotemporal lobar dementia amyotrophic lateral sclerosisimprovedinhibitorinsightmRNA Precursornovelpreventprotein TDP-43prototyperesidencetherapy developmenttoolvector
项目摘要
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are closely-related, fatal
neurodegenerative diseases with considerable genetic and pathologic overlap. Postmortem analysis of more
than 97% of ALS cases and nearly half of FTD cases demonstrates nuclear clearance and cytoplasmic
aggregation of TDP-43, a primarily nuclear DNA- and RNA-binding protein that regulates pre-mRNA splicing.
Moreover, abundant evidence shows that the loss of TDP-43 nuclear function drives the evolution of many
aspects of ALS/FTD pathogenesis. This proposal seeks to build on recent data from our laboratory showing that
RNA critically tethers TDP-43 within the nucleus and limits its passive nuclear export. We propose to design a
novel RNA-based strategy to oppose TDP-43 nuclear export, guided by two observations: 1) TDP-43 nuclear
residence depends on its binding to GU-rich nuclear RNAs, and 2) small GU-rich RNA oligomers transfected into
live cells efficiently target and modulate the nuclear/cytoplasmic shuttling of TDP-43. Here, we will develop
bivalent RNA oligomers, termed TDP-43 nuclear targeting aptamers (TNTAs), to bind and retain the pool of free
TDP-43 that would otherwise diffuse out of the nucleus. The TNTA will consist of a reversible GU-rich TDP-43
targeting sequence (TTS), a linker, and a nucleus-targeting sequence (NTS), to anchor the TNTA-TDP-43
complex within stable nuclear ribonucleoprotein assemblies. Using the (GU)6 sequence as a starting point,
studies in aim 1 will further optimize the TTS motif, using the TDP-43 nuclear displacement assay as a readout
for successful TTS-TDP-43 interaction. Cells will be transfected by synthetic GU-rich RNAs (or poly-A, as a
negative control), and the nuclear exit of endogenous TDP-43 will be monitored by immunofluorescence with
automated confocal high-content microscopy. The direct TTS-TDP-43 interaction, its selectivity towards TDP-
43, and reversibility over time will then be evaluated to identify the optimal TTS sequence. In the second aim,
the nuclear retention sequences of several classes of endogenous nuclear RNAs will be tested to identify optimal
NTS sequences, that, when combined with the TTS can promote TDP-43 nuclear localization. Nuclear tethering
of TNTAs via the bacteriophage MS2-loop RNA-MCP system will be utilized as a positive control. TNTAs
combining the endogenous validated NTS linked to the GU-rich TTS will then be tested for activity in preventing
TDP-43 exit. Finally, the selectivity and reversibility of the TNTAs towards TDP-43 will be determined, and cryptic
exon incorporation will be evaluated to ensure no interference with TDP-43 nuclear function. Together, these
studies will identify and optimize a new tool to promote TDP-43 nuclear localization, to enable further therapy
development and improve our understanding of the regulation of TDP-43 nuclear/cytoplasmic shuttling.
肌萎缩侧索硬化症(ALS)和额颞痴呆(FTD)密切相关,是致命的
神经退行性疾病,有相当大的遗传和病理重叠。更多的尸检分析
超过97%的ALS病例和近一半的FTD病例显示胞核清除和胞浆
TDP-43的聚集,主要是一种核DNA和RNA结合蛋白,调节前mRNA剪接。
此外,大量证据表明,TDP-43核功能的丧失推动了许多
ALS/FTD发病机制的几个方面。这项建议旨在以我们实验室的最新数据为基础,表明
RNA关键地将TDP-43束缚在核内,并限制其被动核出口。我们建议设计一种
基于RNA的反对TDP-43核出口的新策略,由两个观察指导:1)TDP-43核
滞留取决于它与富含Gu的核RNA的结合,以及2)小的富含Gu的RNA寡聚体
活细胞有效地靶向并调节TDP-43的核/胞质穿梭。在这里,我们将发展
二价RNA低聚物,称为TDP-43核靶向适配子(TNTA),用于结合和保留游离池
TDP-43,否则会扩散出细胞核。TNTA将由可逆的富含Gu的TDP-43组成
靶向序列(TTS)、接头和核靶向序列(NTS),以锚定TNTA-TDP-43
稳定的核核糖核蛋白组件中的复合体。使用(GU)6序列作为起点,
目标1中的研究将进一步优化TTS基序,使用TDP-43核置换分析作为读数
以获得成功的TTS-TDP-43相互作用。细胞将被合成的富含GU的RNA(或PolyA,作为一种
阴性对照),并用免疫荧光法监测内源性TDP-43的核退出
自动共聚焦高含量显微镜。TTS-TDP-43的直接相互作用及其对TDP-43的选择性
43,然后将评估随时间的可逆性以确定最佳的TTS序列。在第二个目标中,
将测试几类内源性核RNA的核保留序列,以确定最佳
NTS序列,当与TTS结合时,可以促进TDP-43核定位。核系留
通过噬菌体MS2-loop RNA-MCP系统的TNTAs将被用作阳性对照。TNTAs
将内源性验证的NT与富含GU的TTS相结合,然后将测试其在预防
TDP-43出口。最后,TNTAs对TDP-43的选择性和可逆性将被确定,而且是隐晦的
将对外显子掺入进行评估,以确保不干扰TDP-43的核功能。加在一起,这些
研究将确定和优化一种新的工具来促进TDP-43核定位,以实现进一步的治疗
发展和提高我们对TDP-43核质穿梭调控的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lindsey Renae Hayes其他文献
Lindsey Renae Hayes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lindsey Renae Hayes', 18)}}的其他基金
Development of TDP-43 nuclear targeting aptamers for ALS/FTD
用于 ALS/FTD 的 TDP-43 核靶向适体的开发
- 批准号:
10427644 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10455671 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10640898 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
RNA-based regulation of TDP-43 nuclear export in ALS/FTD
ALS/FTD 中基于 RNA 的 TDP-43 核输出调控
- 批准号:
10285495 - 财政年份:2021
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
10237182 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9431708 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9751978 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
FG-nucleoporins and nuclear transport disruption in C9ORF72-ALS/FTD
C9ORF72-ALS/FTD 中的 FG-核孔蛋白和核运输中断
- 批准号:
9980498 - 财政年份:2017
- 资助金额:
$ 8.19万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 8.19万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 8.19万 - 项目类别:
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
Idea to Innovation
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 8.19万 - 项目类别:
Research Grant














{{item.name}}会员




